| Code | CSB-RA004888MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to VB-119, targeting CD19, a transmembrane glycoprotein exclusively expressed on B cells throughout their development from pre-B cells to mature B lymphocytes. CD19 functions as a critical co-receptor in the B cell receptor complex, modulating B cell activation thresholds and signal transduction pathways. This target plays a significant role in B cell malignancies including B cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia, as well as autoimmune disorders characterized by aberrant B cell activity.
VB-119 serves as the reference antibody for this biosimilar product, providing researchers with a cost-effective alternative for investigating CD19 biology and B cell-mediated pathways. This antibody is valuable for studies examining B cell development, immune regulation, lymphoid tissue organization, and the pathogenesis of B cell-related diseases. It supports research into therapeutic strategies targeting CD19-positive cells and facilitates the characterization of B cell populations in various experimental models.
There are currently no reviews for this product.